Clinical meaning
Carotid body tumors, also known as carotid body paragangliomas or chemodectomas, are rare neuroendocrine neoplasms arising from the paraganglia of the carotid body, a small chemoreceptor organ located at the bifurcation of the common carotid artery into the internal and external carotid arteries. The carotid body is a highly vascularized structure approximately 3-5 mm in diameter that functions as the primary peripheral chemoreceptor for detecting changes in arterial blood oxygen tension (PaO2), carbon dioxide tension (PaCO2), and pH. It plays a critical role in the physiological response to hypoxemia by triggering reflexive increases in respiratory rate, heart rate, and blood pressure through afferent signaling via the glossopharyngeal nerve (cranial nerve IX) to the brainstem respiratory and cardiovascular centers. The carotid body contains two primary cell types: type I (glomus) cells, which are the chemosensory cells derived from neural crest progenitors, and type II (sustentacular) cells, which are supporting glial-like cells that surround and sustain the glomus cells. Type I glomus cells are the cells of origin for carotid body paragangliomas. These cells contain dense-core neurosecretory granules filled with catecholamines (primarily dopamine and norepinephrine), serotonin, and various neuropeptides. Under normal physiological conditions, hypoxemia causes inhibition of oxygen-sensitive potassium channels on the glomus cell membrane, leading to membrane depolarization, calcium influx through voltage-gated calcium channels, and exocytotic release of neurotransmitters that activate afferent glossopharyngeal nerve endings. In carotid body paraganglioma, neoplastic transformation of glomus cells produces unregulated proliferation and tumor growth. The molecular pathogenesis involves mutations in succinate dehydrogenase (SDH) subunit genes (SDHB, SDHC, SDHD), which encode components of mitochondrial complex II in the electron transport chain. SDH catalyzes the oxidation of succinate to fumarate in the tricarboxylic acid (TCA) cycle and simultaneously transfers electrons to ubiquinone in the mitochondrial inner membrane. Loss-of-function mutations in SDH subunits lead to accumulation of succinate, which acts as an oncometabolite by inhibiting prolyl hydroxylase domain (PHD) enzymes. Under normal oxygen conditions, PHD enzymes hydroxylate hypoxia-inducible factor (HIF) alpha subunits, marking them for proteasomal degradation via the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex. When PHD is inhibited by accumulated succinate, HIF-alpha is stabilized even under normoxic conditions, creating a pseudohypoxic cellular state that activates transcription of hypoxia-responsive genes promoting angiogenesis (VEGF), erythropoiesis (EPO), glucose metabolism (GLUT1, glycolytic enzymes), and cell survival pathways. This pseudohypoxic drive is the primary mechanism of tumorigenesis in SDH-mutated paragangliomas. Approximately 30-40% of carotid body paragangliomas are hereditary, following autosomal dominant inheritance patterns with variable penetrance. SDHD mutations are the most common in head and neck paragangliomas and exhibit genomic imprinting -- tumors typically develop only when the mutant allele is inherited from the father (paternal transmission). SDHB mutations are associated with a higher malignancy rate (30-50% vs. 5-10% for other subtypes), increased metastatic potential, and poorer prognosis. Familial paraganglioma syndromes may present with multifocal tumors, bilateral carotid body tumors (present in 30-50% of familial cases vs. 5% of sporadic cases), and concurrent tumors in other paraganglia (vagal, jugulotympanic, retroperitoneal, adrenal). While the majority of carotid body tumors are non-functional (non-secretory), approximately 1-3% are biochemically active and secrete catecholamines (predominantly norepinephrine and dopamine). Functional tumors can cause episodic hypertension, tachycardia, diaphoresis, headache, and palpitations -- a clinical picture indistinguishable from pheochromocytoma. Even in non-secretory tumors, surgical manipulation can trigger massive catecholamine release from the dense-core granules within the tumor cells, causing life-threatening intraoperative hypertensive crises, cardiac arrhythmias, and cardiovascular collapse. This pharmacological consideration necessitates preoperative alpha-adrenergic blockade with phenoxybenzamine in all patients undergoing surgical resection, regardless of preoperative functional status. As carotid body tumors enlarge, they produce symptoms primarily through mass effect and compression of adjacent neurovascular structures. The tumor characteristically grows in the adventitial layer surrounding the carotid bifurcation, splaying apart the internal and external carotid arteries (creating the pathognomonic 'lyre sign' on angiography). Progressive growth leads to compression and displacement of cranial nerves X (vagus), XII (hypoglossal), IX (glossopharyngeal), and the cervical sympathetic chain. Vagus nerve involvement causes vocal cord paralysis and hoarseness; hypoglossal nerve compression produces tongue deviation toward the affected side and dysarthria; glossopharyngeal nerve involvement causes dysphagia and loss of the gag reflex; and sympathetic chain compression produces ipsilateral Horner syndrome. Malignant transformation occurs in approximately 5-10% of carotid body paragangliomas (defined by the presence of metastases to non-paraganglionic tissue, most commonly regional lymph nodes, bone, liver, and lungs, rather than histological criteria, as no reliable histological features distinguish benign from malignant paragangliomas). SDHB mutation carriers have a significantly higher malignancy rate and should undergo lifelong surveillance imaging.